P/E ratio for Lineage Cell Therapeutics (LCTX)
P/E ratio as of May 2024 (TTM): -8.69
According to Lineage Cell Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -8.69231. At the end of 2022 the company had a P/E ratio of -7.80.
P/E ratio history for Lineage Cell Therapeutics from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -7.80 | -17.22% |
| 2021 | -9.42 | -25.04% |
| 2020 | -12.6 | -43.5% |
| 2019 | -22.3 | 755.77% |
| 2018 | -2.60 | -79.44% |
| 2017 | -12.6 | -212.11% |
| 2016 | 11.3 | -262.34% |
| 2015 | -6.95 | 4.33% |
| 2014 | -6.66 | 49.87% |
| 2013 | -4.44 | -39.14% |
| 2012 | -7.30 | -54.75% |
| 2011 | -16.1 | -47.69% |
| 2010 | -30.9 | 16.7% |
| 2009 | -26.4 | 153.92% |
| 2008 | -10.4 | 52.37% |
| 2007 | -6.83 | 102.47% |
| 2006 | -3.38 | 19.76% |
| 2005 | -2.82 | -66.41% |
| 2004 | -8.39 | -20.97% |
| 2003 | -10.6 | 57.52% |
| 2002 | -6.74 | -54.07% |
| 2001 | -14.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -4.28 | -50.76% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.